| Overview |
| bsm-63042r-rbitc-100ul |
| MEK2 Monoclonal Antibody, RBITC Conjugated |
| WB, IF |
| Human, Mouse |
| Specifications |
| RBITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MAPKK2 |
| Monoclonal |
| IgG |
| Lot Dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5605 |
| P36507 |
| Cytoplasm, Cell membrane |
| Cardiofaciocutaneous syndrome; CFC syndrome; Dual specificity mitogen activated protein kinase kinase 2; Dual specificity mitogen-activated protein kinase kinase 2; ERK activator kinase 2; FLJ26075; MAP kinase kinase 2; MAP2K 2; map2k2; MAPK / ERK kinase 2; MAPK/ERK kinase 2; MAPKK 2; MAPKK2; MEK 2; MEK2; Microtubule Associated Protein Kinase Kinase 2; Mitogen activated protein kinase kinase 2; Mitogen activated protein kinase kinase 2 p45; MKK 2; MP2K2_HUMAN; OTTHUMP00000165826; OTTHUMP00000165827; PRKMK 2; PRKMK2 V. |
| Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases. |
| Application Dilution |
| WB |
1:300-5000 |
| IF |
|
Powered by Bioz